Hemgenix

Hemgenix is a gene‑therapy product whose active ingredient is etranacogene dezaparvovec, supplied as a vector solution for intravenous infusion. It is authorized in the European Union for prescription use. The therapy delivers a functional factor IX gene via an adeno‑associated virus (AAV) vector, enabling patients with hemophilia B to produce clotting factor IX endogenously. The treatment is administered as a single infusion and is intended for patients with severe factor IX deficiency.

Hemgenix is indicated for the long‑term management of hemophilia B, a genetic deficiency of clotting factor IX.

- Patients with severe hemophilia B (factor IX activity less than 1%). - Patients with moderately severe hemophilia B (factor IX activity 1–5%). - Individuals who have developed inhibitors to factor IX replacement therapy. - Patients for whom regular factor IX infusions are impractical. - Use as part of a comprehensive hemophilia care program.

Common side effects are generally mild and related to the infusion process.

Common: - Transient fever or chills. - Headache. - Fatigue or malaise. - Nausea or mild gastrointestinal upset. - Transient elevation of liver enzymes. - Mild infusion‑related reactions (e.g., erythema, itching).

Serious: - Thrombotic events. - Severe liver injury or hepatitis. - Immune‑mediated reactions, including anaphylaxis. - Insertional mutagenesis (theoretical risk). - Development of neutralizing antibodies against the AAV vector. - Severe hypersensitivity reactions.

Patients should be evaluated carefully before receiving Hemgenix.

- Screen for pre‑existing AAV antibodies that could reduce efficacy. - Monitor liver function tests before and after infusion. - Use with caution in patients with active hepatitis or liver disease. - The safety of Hemgenix in pregnancy and lactation is unknown; avoid use unless benefits outweigh risks. - Long‑term effects of gene therapy are still being studied; ongoing follow‑up is recommended. - Not recommended for individuals with severe immunodeficiency. - Ensure appropriate vaccination status, avoiding live vaccines shortly after infusion.

Hemgenix may interact with other therapies that affect clotting or immune response.

Avoid: - Concurrent administration of other experimental gene‑therapy products. - High‑dose immunosuppressive agents that could impair vector efficacy.

Use with caution: - Anticoagulants or antiplatelet drugs, which may alter bleeding risk. - Other factor IX replacement products, especially during the peri‑infusion period. - Live vaccines administered within 4 weeks of infusion. - Hepatotoxic medications that could compound liver enzyme elevations. - Immunomodulatory therapies that may affect the development of neutralizing antibodies.